Investor Relations > details

Zensun´s rhNRG-1 Project has passed the Preliminary Evaluation by Boehringer-Ingelheim

2006-03-02

In April 15, 2003, Boehringer-Ingelheim finished the preliminary evaluation of anti-heart failure drug—rhNRG-1. In late April, more detailed data was provided by Zensun to undergo the second round of evaluation.

More

地址:上海市浦东张江高科技园区居里路68号沪ICP备06030993号-3